MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:32Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Calcium channel blockers]]
			[[Category:Antianginals]]
			[[Category:Antiarrhythmics]]
			[[Category:Antihypertensives]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #106

2026-05-23T03:46:15Z

parser-claude batch MedTemplate pre-fill, Top 300 #106

New page

{{MedTemplate
| generic = Diltiazem
| brand = Cardizem, Tiazac, Cartia XT, Dilacor XR, Taztia XT, Matzim LA
| structure =
| classes = [[:Category:Calcium_channel_blockers|Calcium channel blocker (non-dihydropyridine)]], [[:Category:Antianginals|Antianginal]], [[:Category:Antiarrhythmics|Antiarrhythmic (class IV)]], [[:Category:Antihypertensives|Antihypertensive]]
| uses = <vote slug="hypertension-use">Hypertension</vote>, <vote slug="stable-angina-use">Stable and vasospastic angina</vote>, <vote slug="afib-rate-control-use">Atrial fibrillation rate control</vote>, <vote slug="psvt-use">Paroxysmal SVT (acute IV)</vote>
| starting_dose = ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion
| preparations = IR 30, 60, 90, 120 mg tablets; multiple ER capsules and tablets 60-420 mg; IV 5 mg/mL
| fda_max = ~480 mg/d (oral); IV per protocol
| pill_id =
| routes = Oral (IR, multiple ER formulations), IV
| onset = IV: 3-7 minutes (rate control); PO IR: 30-60 minutes; ER: hours
| duration = IR: 4-8 hours; ER: 24 hours
| halflife = 3-4.5 hours (IR); 5-7 hours (ER; effective duration 24 hours via formulation)<ref name="cardizem-label">FDA Prescribing Information, Cardizem (diltiazem HCl), Sun Pharma, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018602s055lbl.pdf</ref>
| bioavailability = ~40% (oral; extensive first-pass via CYP3A4)<ref name="cardizem-label" />
| pregnancy = Limited data; labetalol/nifedipine generally preferred. Crosses placenta.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="diltiazem-mech-claim">Diltiazem is a benzothiazepine non-dihydropyridine calcium channel blocker; unlike amlodipine and nifedipine, it has substantial AV nodal and cardiac myocyte L-type channel blockade in addition to vascular smooth muscle effects, producing rate control plus modest vasodilation.</vote> Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates<ref name="cardizem-label" />.
}}

== References ==
<references />

Diltiazem - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #106